SV
Saturn V Capital Management LP
13F filer · CIK 0001964437Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$697MU.S. long equity reported on 13F
Positions233 new · 1 closed
Net flow last quarter+$44.8MBuys minus sells
Top 10 positions weight75.6%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202623 positions | |||||
| $83M | 11.91% | 4.15% | +6.3% | Q3 2023 | |
| $82M | 11.76% | Not reported | -9.0% | Q4 2025 | |
| $69.1M | 9.91% | 0.66% | -4.4% | Q1 2024 | |
| $49.6M | 7.11% | 0.59% | +3.4% | Q1 2024 | |
| $48M | 6.89% | 6.51% | +26.1% | Q4 2025 | |
| $45.4M | 6.52% | 2.02% | +9.4% | Q3 2025 | |
| $38.8M | 5.56% | 0.26% | -1.2% | Q2 2025 | |
| $38.7M | 5.55% | 0.76% | +31.4% | Q2 2024 | |
| $38.4M | 5.50% | 1.37% | +16.6% | Q4 2023 | |
| $34M | 4.88% | 4.34% | +14.1% | Q1 2026 | |
| $32.6M | 4.67% | 7.26% | +8.0% | Q4 2025 | |
| $28.9M | 4.14% | 4.65% | -9.7% | Q3 2025 | |
| $23.5M | 3.37% | 0.64% | +9.4% | Q2 2025 | |
| $19.6M | 2.81% | 0.74% | New | Q2 2026 | |
| $12.4M | 1.78% | 2.20% | +184.0% | Q1 2026 | |
| $11.4M | 1.64% | 4.82% | New | Q2 2026 | |
| $9.5M | 1.36% | Not reported | +32.5% | Q4 2025 | |
| $7.85M | 1.13% | 2.93% | +0.2% | Q4 2025 | |
| $7.85M | 1.13% | 0.46% | New | Q2 2026 | |
| $7.32M | 1.05% | 2.85% | -23.4% | Q4 2025 | |
| $4.82M | 0.69% | 0.52% | +105.4% | Q1 2026 | |
| $2.72M | 0.39% | 27.17% | Not reported | Q1 2026 | |
| $1.78M | 0.26% | 0.36% | -84.1% | Q4 2025 | |
| Q1 2026Reported May 15, 202621 positions | |||||
| $70.5M | 12.77% | Not reported | +2.1% | Q4 2025 | |
| $60.5M | 10.95% | 3.92% | -3.3% | Q3 2023 | |
| $60.4M | 10.94% | 0.69% | -16.4% | Q1 2024 | |
| $47.9M | 8.68% | 0.57% | +3.2% | Q1 2024 | |
| $33.9M | 6.15% | 1.84% | +5.4% | Q3 2025 | |
| $33.6M | 6.09% | 6.97% | +23.2% | Q4 2025 | |
| $32.2M | 5.83% | 0.58% | -11.1% | Q2 2024 | |
| $30.8M | 5.58% | 0.26% | -34.3% | Q2 2025 | |
| $28.8M | 5.21% | 1.18% | +50.8% | Q4 2023 | |
| $26.7M | 4.83% | 6.85% | +11.3% | Q4 2025 | |
| $24.1M | 4.37% | 0.37% | -48.5% | Q2 2023 | |
| $18.9M | 3.43% | 5.16% | +6.1% | Q3 2025 | |
| $17.5M | 3.17% | 0.59% | -46.0% | Q2 2025 | |
| $14.2M | 2.58% | 3.87% | +41.6% | Q4 2025 | |
| $14.2M | 2.57% | 3.95% | New | Q1 2026 | |
| $13.7M | 2.49% | Not reported | Not reported | Q4 2025 | |
| $9.25M | 1.68% | 2.49% | +66.7% | Q4 2025 | |
| $6.49M | 1.18% | 2.93% | +0.2% | Q4 2025 | |
| $4.4M | 0.80% | 0.78% | New | Q1 2026 | |
| $2M | 0.36% | 0.25% | New | Q1 2026 | |
| $1.97M | 0.36% | 27.17% | New | Q1 2026 | |
| Q4 2025Reported Feb 17, 202620 positions | |||||
| $87.5M | 16.07% | 0.83% | -19.0% | Q1 2024 | |
| $54.3M | 9.97% | 4.09% | -2.4% | Q3 2023 | |
| $43.2M | 7.93% | 0.76% | -39.9% | Q2 2023 | |
| $42.2M | 7.74% | 0.40% | -17.5% | Q2 2025 | |
| $36.9M | 6.77% | 0.61% | +1.3% | Q1 2024 | |
| $35M | 6.42% | 1.08% | -33.1% | Q2 2025 | |
| $31.6M | 5.81% | 1.75% | +28.6% | Q3 2025 | |
| $31.6M | 5.80% | 0.66% | -33.1% | Q2 2024 | |
| $30.6M | 5.62% | Not reported | New | Q4 2025 | |
| $23.7M | 4.35% | 0.79% | -12.5% | Q4 2023 | |
| $23.2M | 4.26% | 6.38% | New | Q4 2025 | |
| $21.3M | 3.90% | 4.87% | +109.6% | Q3 2025 | |
| $19.1M | 3.51% | 2.74% | New | Q4 2025 | |
| $18.3M | 3.35% | 0.70% | +30.7% | Q4 2024 | |
| $15.7M | 2.88% | 5.66% | New | Q4 2025 | |
| $10.3M | 1.89% | Not reported | New | Q4 2025 | |
| $7.91M | 1.45% | 2.93% | New | Q4 2025 | |
| CPCNTACentessa Pharmaceuticals PLC | $7.07M | 1.30% | 0.19% | -61.5% | Q1 2025 |
| $4.08M | 0.75% | 1.92% | New | Q4 2025 | |
| $1.32M | 0.24% | 0.15% | New | Q4 2025 | |
| Q3 2025Reported Nov 14, 202517 positions | |||||
| $68M | 14.92% | 1.26% | +28.7% | Q1 2024 | |
| $62.6M | 13.72% | 4.20% | +41.2% | Q3 2023 | |
| $39.6M | 8.69% | 0.50% | +45.3% | Q2 2025 | |
| $33.8M | 7.42% | 1.88% | +83.8% | Q2 2025 | |
| $29.1M | 6.38% | 1.45% | -11.9% | Q2 2023 | |
| $28.4M | 6.23% | 0.61% | +44.9% | Q1 2024 | |
| $23.4M | 5.13% | 1.09% | -60.0% | Q2 2024 | |
| $23.4M | 5.12% | 0.74% | -1.2% | Q3 2024 | |
| $22.5M | 4.94% | 0.97% | -13.9% | Q4 2023 | |
| $22.1M | 4.85% | 1.63% | New | Q3 2025 | |
| $20.2M | 4.44% | 0.65% | +7.5% | Q4 2024 | |
| CPCNTACentessa Pharmaceuticals PLC | $17.8M | 3.91% | 0.55% | -7.4% | Q1 2025 |
| MMRUSMerus N.V. | $17.3M | 3.80% | 0.24% | -17.9% | Q3 2023 |
| $17.1M | 3.76% | 1.29% | +7.6% | Q2 2025 | |
| $13.5M | 2.95% | 0.66% | +58.1% | Q4 2024 | |
| $12.7M | 2.78% | 2.33% | New | Q3 2025 | |
| $4.36M | 0.96% | 0.14% | -30.6% | Q4 2024 | |
Premium opens every quarter this fund has filed